CGEM — Cullinan Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1789972 ·
Last close
$15.53
Market Cap
$954.44M
52W High
$23.19
52W Low
$6.73
ADV30
1,163,139
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -57,254,000 | -53,704,000 | 363,787,000 | 78,640,000 | 42,033,000 |
| Mar 2026 | 0 | — | -53,697,000 | -49,661,000 | 402,984,000 | 75,081,000 | 36,812,000 |
| Dec 2025 | 0 | — | -55,259,000 | -50,713,000 | 448,374,000 | 88,332,000 | 39,644,000 |
| Sep 2025 | 0 | — | -55,595,000 | -50,610,000 | 484,126,000 | 103,335,000 | 32,757,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-159,250,000
Investing CF
$162,875,000
Financing CF
$2,195,000
CapEx
$-11,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.10
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-691,484,000
Inventory
—
Receivables
—
ST Investments
$255,898,000
EBIT TTM
$-221,805,000
Pretax Income TTM
$-204,688,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -241,648,000 | -219,879,000 | 448,374,000 | 39,644,000 | 408,730,000 | -175,750,000 |
| Dec 2024 | 0 | -196,919,000 | -167,383,000 | 621,824,000 | 31,496,000 | 590,328,000 | -145,303,000 |
| Dec 2023 | 0 | -190,649,000 | -153,162,000 | 484,182,000 | 30,287,000 | 453,703,000 | -134,275,000 |
| Dec 2022 | 0 | -132,137,000 | 111,214,000 | 561,117,000 | 26,088,000 | 535,029,000 | -126,664,000 |
TTM Snapshot
Revenues TTM
$19,730,000
NetIncome TTM
$-221,039,000
OpCashFlow TTM
—
Assets (Latest)
$402,984,000
Forward EPS
$-2.71
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $913.11M | $19.00 | — |
| MGTX | MeiraGTx Holdings plc | $1.03B | $10.69 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $878.73M | $10.30 | — |
| SLBT | SL Science Holding Ltd | $846.75M | $1.51 | — |
| SANA | Sana Biotechnology, Inc. | $835.22M | $2.79 | — |
News headlines (Yahoo Finance, 1h cache)
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia
2026-10-08 11:00 · Yahoo
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
2026-09-28 11:02 · Yahoo
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
2026-09-26 22:07 · Yahoo
CGEM Stock Extends Losses After Cullinan Delays Arthritis Update To December — Zipalertinib Safety Worries Linger
2026-09-24 19:08 · Yahoo
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
2026-09-24 13:57 · Yahoo
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
2026-09-24 11:00 · Yahoo
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data
2026-09-24 10:12 · Yahoo
Cullinan Therapeutics (CGEM) Reports a Six-Month PFS Gain. Can it Justify Higher Toxicity?
2026-09-17 04:00 · Yahoo
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results
2026-09-14 14:09 · Yahoo
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
2026-09-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.